Logo image of OBIO

ORCHESTRA BIOMED HOLDINGS IN (OBIO) Stock Fundamental Analysis

NASDAQ:OBIO - Nasdaq - US68572M1062 - Common Stock - Currency: USD

2.92  -0.08 (-2.67%)

After market: 2.95 +0.03 (+1.03%)

Fundamental Rating

2

Taking everything into account, OBIO scores 2 out of 10 in our fundamental rating. OBIO was compared to 187 industry peers in the Health Care Equipment & Supplies industry. OBIO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, OBIO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

OBIO had negative earnings in the past year.
OBIO had a negative operating cash flow in the past year.
In the past 5 years OBIO always reported negative net income.
OBIO had a negative operating cash flow in each of the past 5 years.
OBIO Yearly Net Income VS EBIT VS OCF VS FCFOBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

OBIO has a worse Return On Assets (-112.30%) than 83.96% of its industry peers.
The Return On Equity of OBIO (-393.40%) is worse than 87.17% of its industry peers.
Industry RankSector Rank
ROA -112.3%
ROE -393.4%
ROIC N/A
ROA(3y)-56.32%
ROA(5y)-79.02%
ROE(3y)-108.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OBIO Yearly ROA, ROE, ROICOBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

Looking at the Gross Margin, with a value of 92.58%, OBIO belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
OBIO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for OBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.78%
GM growth 5YN/A
OBIO Yearly Profit, Operating, Gross MarginsOBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 1K -1K 2K -2K

More info and screens

3

2. Health

2.1 Basic Checks

OBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OBIO has more shares outstanding
The debt/assets ratio for OBIO is higher compared to a year ago.
OBIO Yearly Shares OutstandingOBIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
OBIO Yearly Total Debt VS Total AssetsOBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

OBIO has an Altman-Z score of -9.21. This is a bad value and indicates that OBIO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -9.21, OBIO is not doing good in the industry: 79.68% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.85 indicates that OBIO is somewhat dependend on debt financing.
The Debt to Equity ratio of OBIO (0.85) is worse than 75.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Altman-Z -9.21
ROIC/WACCN/A
WACC8.76%
OBIO Yearly LT Debt VS Equity VS FCFOBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 3.35 indicates that OBIO has no problem at all paying its short term obligations.
The Current ratio of OBIO (3.35) is comparable to the rest of the industry.
A Quick Ratio of 3.34 indicates that OBIO has no problem at all paying its short term obligations.
OBIO has a Quick ratio of 3.34. This is in the better half of the industry: OBIO outperforms 66.84% of its industry peers.
Industry RankSector Rank
Current Ratio 3.35
Quick Ratio 3.34
OBIO Yearly Current Assets VS Current LiabilitesOBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for OBIO have decreased strongly by -19.59% in the last year.
Looking at the last year, OBIO shows a very strong growth in Revenue. The Revenue has grown by 29.88%.
EPS 1Y (TTM)-19.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.95%
Revenue 1Y (TTM)29.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40%

3.2 Future

OBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.10% yearly.
The Revenue is expected to grow by 76.15% on average over the next years. This is a very strong growth
EPS Next Y-22.7%
EPS Next 2Y-3.3%
EPS Next 3Y-1.96%
EPS Next 5Y11.1%
Revenue Next Year-6.03%
Revenue Next 2Y2.34%
Revenue Next 3Y2.21%
Revenue Next 5Y76.15%

3.3 Evolution

OBIO Yearly Revenue VS EstimatesOBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50M 100M 150M
OBIO Yearly EPS VS EstimatesOBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OBIO Price Earnings VS Forward Price EarningsOBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OBIO Per share dataOBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.3%
EPS Next 3Y-1.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORCHESTRA BIOMED HOLDINGS IN

NASDAQ:OBIO (7/11/2025, 8:00:02 PM)

After market: 2.95 +0.03 (+1.03%)

2.92

-0.08 (-2.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners37.42%
Inst Owner Change0%
Ins Owners3.2%
Ins Owner Change4.16%
Market Cap111.87M
Analysts84.62
Price Target13.84 (373.97%)
Short Float %4.2%
Short Ratio1.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.13%
Max EPS beat(2)3.57%
EPS beat(4)3
Avg EPS beat(4)-0.53%
Min EPS beat(4)-12.33%
Max EPS beat(4)6.52%
EPS beat(8)7
Avg EPS beat(8)3.72%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-4.44%
Min Revenue beat(2)-70.51%
Max Revenue beat(2)61.63%
Revenue beat(4)2
Avg Revenue beat(4)4.12%
Min Revenue beat(4)-70.51%
Max Revenue beat(4)61.63%
Revenue beat(8)3
Avg Revenue beat(8)-14.98%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.06%
PT rev (3m)-5.32%
EPS NQ rev (1m)0.35%
EPS NQ rev (3m)-3.64%
EPS NY rev (1m)0.24%
EPS NY rev (3m)-3.61%
Revenue NQ rev (1m)-13%
Revenue NQ rev (3m)-22.21%
Revenue NY rev (1m)-7.18%
Revenue NY rev (3m)-21.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 38.76
P/FCF N/A
P/OCF N/A
P/B 6.64
P/tB 6.64
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-1.77
Fwd EYN/A
FCF(TTM)-1.44
FCFYN/A
OCF(TTM)-1.41
OCFYN/A
SpS0.08
BVpS0.44
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -112.3%
ROE -393.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.58%
FCFM N/A
ROA(3y)-56.32%
ROA(5y)-79.02%
ROE(3y)-108.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.78%
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 313.88%
Cap/Sales 34.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.35
Quick Ratio 3.34
Altman-Z -9.21
F-Score3
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)194.88%
Cap/Depr(5y)224.07%
Cap/Sales(3y)17.77%
Cap/Sales(5y)19.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.95%
EPS Next Y-22.7%
EPS Next 2Y-3.3%
EPS Next 3Y-1.96%
EPS Next 5Y11.1%
Revenue 1Y (TTM)29.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40%
Revenue Next Year-6.03%
Revenue Next 2Y2.34%
Revenue Next 3Y2.21%
Revenue Next 5Y76.15%
EBIT growth 1Y-26.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.05%
EBIT Next 3Y-12%
EBIT Next 5Y2.91%
FCF growth 1Y-41.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.96%
OCF growth 3YN/A
OCF growth 5YN/A